Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trial.
Anna J M van de SandeRomy van BaarsMargot M KoenemanCornelis G GeresteinArnold-Jan KruseEdith M G van EschPeggy J de Vos van SteenwijkCaroline L P MuntingaSten Paul WillemsenH Lena C van DoornFolkert van KemenadeHeleen van BeekhuizenPublished in: BJOG : an international journal of obstetrics and gynaecology (2024)
This is the first randomised controlled trial to show that topical imiquimod has a significantly lower success rate in terms of reduction to normal cytology and hr-HPV clearance, compared with LLETZ, in women with rrCIN. Additionally, imiquimod has numerous side effects and after using imiquimod most women with rrCIN still required additional surgical treatment.